Paul E. Yestrumskas
Nessuna posizione attualmente
Provenienza dei contatti di primo grado di Paul E. Yestrumskas
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Rhône-Poulenc, Inc.
2
| Extinct | Chemicals: Specialty | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Paul E. Yestrumskas tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| GOLD HORSE INTERNATIONAL INC | Engineering & Construction | Director/Board Member | |
Institut de Recherches Internationales Servier
 Institut de Recherches Internationales Servier Miscellaneous Commercial ServicesCommercial Services Part of Servier SAS, Institut de Recherches Internationales Servier is a French company that provides scientific research and development services. The company is based in Suresnes, France. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
NETRIS Pharma SAS
 NETRIS Pharma SAS BiotechnologyHealth Technology NETRIS Pharma SAS develops targeted therapies for the treatment of cancer. The company is based in Lyon, France. The French company was founded in 2008 by Patrick Mehlen, Agnès Bernet. Patrick Mehlen has been the CEO since 2008. | Biotechnology | Chairman | |
| ADC THERAPEUTICS SA | Pharmaceuticals: Major | Director/Board Member | |
Rhone Poulenc Rorer
 Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | Chemicals: Specialty | Corporate Officer/Principal | |
International Drug Development Institute SA
 International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
| Aventis, Inc. | Chief Tech/Sci/R&D Officer | ||
| COMPUGEN LTD. | Biotechnology | Director/Board Member | |
Synergie Lyon Cancer
 Synergie Lyon Cancer Miscellaneous Commercial ServicesCommercial Services Synergie Lyon Cancer provides health care services. It focuses on research efforts on cancer escape, apoptosis and senescence and Immune surveillance. The company was founded in 2007 and is headquartered in Lyon, France. | Miscellaneous Commercial Services | President | |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
| Sanofi-Aventis Pharmaceuticals | Corporate Officer/Principal | ||
| Thunderbird School of Global Management | College/University | Corporate Officer/Principal | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member | |
| European Organisation for Research & Treatment of Cancer | Director/Board Member | ||
| CELGENE | Biotechnology | Corporate Officer/Principal | |
Theravectys SAS
 Theravectys SAS BiotechnologyHealth Technology Theravectys SAS provides biotechnology research services. It is working on the development of a therapeutic vaccine against HIV. The company was founded on May 17, 2005 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
| PIERIS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
| University of Nice Sophia Antipolis | College/University | Doctorate Degree | |
| CELATOR PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
| HALOZYME THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| TRANSGENE | Biotechnology | Director/Board Member | |
University of Miami
 University of Miami Other Consumer ServicesConsumer Services University of Miami (Florida) is a private research university with students from around the world that is focused on teaching and learning, the discovery of new knowledge, and service to the South Florida region and beyond. The university was founded in 1925 and it is headquartered in Coral Gables, FL. | College/University | Corporate Officer/Principal | |
| CONAGRA BRANDS, INC. | Food: Major Diversified | President | |
| APREA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 12 |
| Francia | 9 |
| Belgio | 4 |
| Cina | 2 |
| Svizzera | 2 |
Settori
| Health Technology | 16 |
| Commercial Services | 4 |
| Consumer Services | 4 |
| Industrial Services | 2 |
| Process Industries | 2 |
Posizioni
| Director/Board Member | 16 |
| Corporate Officer/Principal | 9 |
| Independent Dir/Board Member | 8 |
| President | 2 |
| Chairman | 1 |
Contatti più connessi
| Insiders | |
|---|---|
| Jean Bizzari | 24 |
| Noel Robyn | 5 |
- Borsa valori
- Insiders
- Paul E. Yestrumskas
- Connessioni Società
